

# Xing Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3734555/publications.pdf>

Version: 2024-02-01

11  
papers

214  
citations

1040056

9  
h-index

1281871

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

353  
citing authors

#	ARTICLE	IF	CITATIONS
1	InÂvitro and inÂvivo anti-tumor activity of two gold(III) complexes with isoquinoline derivatives as ligands. <i>European Journal of Medicinal Chemistry</i> , 2019, 163, 333-343.	5.5	31
2	Rhodium(III) complexes with isoquinoline derivatives as potential anticancer agents: <i>in vitro</i> and <i>in vivo</i> activity studies. <i>Dalton Transactions</i> , 2019, 48, 11469-11479.	3.3	27
3	A Novel Naphthalimide Compound Restores p53 Function in Non-small Cell Lung Cancer by Reorganizing the Bak-Bcl-xl Complex and Triggering Transcriptional Regulation. <i>Journal of Biological Chemistry</i> , 2016, 291, 4211-4225.	3.4	26
4	Three novel transition metal complexes of 6-methyl-2-oxo-quinoline-3-carbaldehyde thiosemicarbazone: synthesis, crystal structure, cytotoxicity, and mechanism of action. <i>RSC Advances</i> , 2017, 7, 17923-17933.	3.6	26
5	Design, synthesis and pharmacological evaluation of new 3-(1H-benzimidazol-2-yl)quinolin-2(1H)-one derivatives as potential antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 139-150.	5.5	25
6	Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9154-9167.	6.4	25
7	Discovery of $\hat{2}$ -carboline copper(II) complexes as Mcl-1 inhibitor and <i>in vitro</i> and <i>in vivo</i> activity in cancer models. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111567.	5.5	23
8	Preparation of Rhodium(III) complexes with 2(1H)-quinolinone derivatives and evaluation of their <i>in vitro</i> and <i>in vivo</i> antitumor activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 226-236.	5.5	14
9	A $\hat{2}$ -carboline derivative-based nickel(II) complex as a potential antitumor agent: synthesis, characterization, and cytotoxicity. <i>MedChemComm</i> , 2018, 9, 100-107.	3.4	11
10	Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents. <i>Current Molecular Medicine</i> , 2021, 21, 426-439.	1.3	5
11	Mitochondrion-Targeting Identification of a Fluorescent Apoptosis-Triggering Molecule by Mass Spectrometry Elucidates Drug Tracking. <i>ChemBioChem</i> , 2019, 20, 778-784.	2.6	1